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PCR using allele-specific probes, and CYP2C9*3 by PCR-RFLP. PHT 
plasma levels were determined by radioimmunoassay.
Results: Twenty-six patients showed PHT therapeutic levels (10–20 
µg/mL), 24 subtherapeutic and 7 supratherapeutic. Three cases, 
2 CYP2C9 *1/*2, and 1 CYP2C19*1/3, had subtherapeutic levels. 
Patients with wild-type ABCB1 and ABCC2 genotypes exhibited a 
tendency to have increased PHT plasma levels than patients with 
mutant genotypes.
Conclusion: PHT plasma levels showed great variability among 
patients that was not statistically significant correlated to the genetic 
polymorphisms analyzed, although ABCB1 and ABCC2 wild-type 
genotypes showed a trend toward higher levels. Further investigations 
are needed with other candidate genes and a larger sample.
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Introduction: Aspirin is an antiplatelet agent commonly used in 
treatment of patients with high risk to develop stroke and myocar-
dial infarction. However, interindividual variability regarding the 
inhibition of platelet function by aspirin is well documented. In this 
study, the correlation between platelet glycoproteins (GPIa C807T 
and GPIba C-5T) and cyclooxygenase 2 (COX-2 G-765C) poly-
morphisms and antiplatelet response in patients treated with aspirin 
was investigated.
Patients (or Materials) and Methods: Jordanian adult patients 
(n = 584) who are taking aspirin as an antiplatelet agent partici-
pated in the study. Platelet aggregation response was measured using 
Multiplate Analyzer® system. Polymerase chain reaction–restriction 
fragment length polymorphism assay (PCR-RFLP) was used for geno-
typing of the examined polymorphisms.
Results: Aspirin resistance was found in 15.8% of patients. Response 
to aspirin was significantly associated with GPIba C-5T polymor-
phism (P < 0.05). However, the GPIa C807T and COX-2 G-765C 
polymorphisms were not related to aspirin resistance (P > 0.05).
Conclusion: A considerable fraction of the Jordanian population is 
resistant to the antiplatelet effect of aspirin, which might be related 
to GPIba C-5T polymorphism.
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Introduction: Pharmacogenomics is intervening in cardiovascular 
therapeutic armamentarium to tailor therapy to individual’s genetic 
makeup. Accordingly, the potential implication of PlA gene variants 
of GPIIIa of platelet GP IIb/IIIa as a genetic risk factor provocateur 
and/or a therapeutic outcome modulator to antiplatelet therapy in 
ACS was probed.
Patients (or Materials) and Methods: Study enrolled 22 controls 
and 44 ACS patients (NSTEMI vs STEMI). They were risk strati-
fied (TIMI score), sampled for genotyping and estimation of plate-
let aggregation and oxidative indices, then subdivided according to 
add-on antiplatelet therapy into: clopidogrel or tirofiban subgroups. 
After 48 hours, the therapeutic outcome was assessed; clinically [pain 
relief or complication prevalence (symptomatic, electrocardiographic, 
or hemorrhagic) and the investigational estimates were re-assessed. 
Intraprocedural evaluation of chest pain, ECG tracing, and angio-
graphic findings (thrombus extent, TIMI flow, myocardial blush) 
were reported in patients who underwent percutaneous intervention 
[PCI].
Results: Frequency of PlA2 vs PlA1 allele was higher in ACS patients 
(significant in < 60 years /doubled in STEMI vs NSTEMI). TIMI 
score, stratification permitted considering PlA2 variant as inde-
pendent risk factor in UA/NSTEMI subsets. This was fostered by 
intraprocedural finding of more stenotic and thrombotic lesions in 
PlA2 carriers. A lack of significant association between PlA variants 
and changes in platelet aggregation or oxidative indices, debate their 
causal relation to PlA2 variant being an ACS risk factor. A positive 
correlation was observed between PlA variants and the therapeutic 
response outcome to both clopidogrel and tirofiban regarding platelet 
aggregation and relief of chest pain while their antioxidative poten-
tiality was negatively correlated only to PlA1 carriers.
Conclusion: PlA2 variant could be considered a genetic risk factor 
contributor rather than an antiplatelet therapeutic response modula-
tor when speaking of ACS. This awaits larger scale pharmacogenomic 
studies before a final statement is declared so as to individualize anti-
platelet therapy to the best of its therapeutic outcome in ACS settings.
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Introduction: Ultrarapid drug metabolism (UM) mediated by 
CYP2D6 is associated with duplicated or amplified functional 
CYP2D6 alleles. However, duplicated CYP2D6 alleles only explains 
a fraction (10%–30%) of the UM phenotype observed in Caucasian 
populations, and other biochemical and/or genetic factors involved 
in UM phenotype remain unexplained yet. CYP2D6 -1584C> G has 
been related with changes in CYP2D6 expression, being -1584G 
associated with higher expression. The aim of this study was to 
explore the relationship between CYP2D6 -1584C> G polymorphism 
and the debrisoquine hydroxylation capacity.
